# Semaglutide linked to fewer asthma attacks

> A large UK records study associated semaglutide with nearly 40% fewer asthma attacks, but the conference result cannot show that the drug caused the difference.

_Source: European Respiratory Society conference release, independently contextualized by MedPage Today; observational results, not a randomized trial or peer-reviewed paper · 2026-09-09 · 6 min read · Verified against primary sources_

Canonical: https://iyu.app/e/semaglutide-asthma-attacks-observational-study

## The 60-second version

Semaglutide users had fewer asthma attacks in a large UK records analysis, but the result is observational and not proof of an asthma treatment.

**Key points**

- Four parallel studies each included about 20,000 to 22,000 people.
- Semaglutide showed the strongest reported association: nearly 40% fewer asthma attacks.
- COPD flare-ups were also reported about 20% lower with semaglutide.
- Randomized trials must test lung outcomes and separate drug effects from weight loss and confounding.

**Verdict.** A credible reason to run a trial, not a reason to change prescriptions today.

## Full explainer

> **⚑ Caveat:** Evidence boundary: these are observational results presented at a conference. They show an association, not that semaglutide caused fewer attacks, and no peer-reviewed paper or public DOI for this analysis was identified at publication time.


### The signal — What the researchers reported

A UK electronic-health-record study linked **semaglutide** with nearly **40% fewer asthma attacks**. The same analysis reported about **20% fewer COPD flare-ups**. Both figures describe associations in routine care, not effects established by random assignment.

The Imperial College London-led team presented the work at the European Respiratory Society Congress in Barcelona. It ran four parallel studies, each following roughly **20,000 to 22,000 people** who started a GLP-1 receptor agonist or a sulfonylurea for an existing metabolic indication.

- **~40%** — reported association with fewer asthma attacks for semaglutide
- **~20%** — reported association with fewer COPD flare-ups
- **4** — parallel real-world record studies


### Study design — A useful comparison, but not randomization

Using sulfonylurea starters as the comparison group is stronger than comparing GLP-1 users with everyone else: both groups had a clinical reason to receive glucose-lowering medicine. Yet doctors and patients still chose treatment in ordinary care, so the groups may differ in ways the records cannot fully capture.

- **What the study can say:** Attack rates differed between treatment groups after a real-world comparison.
- **What it cannot say:** Semaglutide itself caused the difference or should be prescribed for asthma.
- **What comes next:** Peer-reviewed methods and randomized trials with respiratory outcomes.


### Possible pathways — Why metabolism and airways may connect

Obesity and metabolic dysfunction can worsen airway disease through mechanical load, insulin resistance and inflammation. GLP-1 medicines can change weight and metabolic control, and may have anti-inflammatory effects. This study cannot tell whether one of those pathways, several together, or differences between patients explain the signal.


### Uncertainty — The headline number needs a trial

Residual confounding remains possible from prescribing choices, disease severity, smoking, adherence and access to care. The result was a conference presentation; a full peer-reviewed report would be needed to inspect adjustment methods, follow-up, absolute attack rates and subgroup stability.

> A large association can justify a clinical trial. It cannot substitute for one.


### Practical meaning — Do not change asthma treatment yet

People who already qualify for semaglutide for type 2 diabetes or obesity may eventually prove to gain an extra respiratory benefit. For now, the investigators say the finding should not change treatment on its own: continue prescribed inhalers and do not start a GLP-1 drug specifically for asthma or COPD outside current guidance.


## Primary sources

- [European Respiratory Society: conference news release and abstract link](https://www.ersnet.org/news-and-features/news/weight-loss-injection-semaglutide-can-reduce-asthma-attacks-by-up-to-40-per-cent/)
- [MedPage Today: independent ERS Congress report](https://www.medpagetoday.com/meetingcoverage/ers/122928)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._